| Analysis | Samples | Factors | Units |
|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n1_2h_sh-Ctrl_DMSO_4 | Sample source:Breast cancer cells | Genotype:shCtrl | Treatment:DMSO | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n2_2h_sh-Ctrl_DMSO_13 | Sample source:Breast cancer cells | Genotype:shCtrl | Treatment:DMSO | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n3_2h_sh-Ctrl_DMSO_22 | Sample source:Breast cancer cells | Genotype:shCtrl | Treatment:DMSO | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n1_2h_sh-Ctrl_RSL3_10_uM_6 | Sample source:Breast cancer cells | Genotype:shCtrl | Treatment:RSL3 (10 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n2_2h_sh-Ctrl_RSL3_10_uM_15 | Sample source:Breast cancer cells | Genotype:shCtrl | Treatment:RSL3 (10 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n3_2h_sh-Ctrl_RSL3_10_uM_24 | Sample source:Breast cancer cells | Genotype:shCtrl | Treatment:RSL3 (10 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n1_2h_sh-Ctrl_RSL3_1_uM_5 | Sample source:Breast cancer cells | Genotype:shCtrl | Treatment:RSL3 (1 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n2_2h_sh-Ctrl_RSL3_1_uM_14 | Sample source:Breast cancer cells | Genotype:shCtrl | Treatment:RSL3 (1 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n3_2h_sh-Ctrl_RSL3_1_uM_23 | Sample source:Breast cancer cells | Genotype:shCtrl | Treatment:RSL3 (1 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n1_2h_sh-ZEB1_DMSO_7 | Sample source:Breast cancer cells | Genotype:shZeb1 | Treatment:DMSO | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n2_2h_sh-ZEB1_DMSO_16 | Sample source:Breast cancer cells | Genotype:shZeb1 | Treatment:DMSO | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n3_2h_sh-ZEB1_DMSO_25 | Sample source:Breast cancer cells | Genotype:shZeb1 | Treatment:DMSO | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n1_2h_sh-ZEB1_RSL3_10_uM_9 | Sample source:Breast cancer cells | Genotype:shZeb1 | Treatment:RSL3 (10 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n2_2h_sh-ZEB1_RSL3_10_uM_18 | Sample source:Breast cancer cells | Genotype:shZeb1 | Treatment:RSL3 (10 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n3_2h_sh-ZEB1_RSL3_10_uM_27 | Sample source:Breast cancer cells | Genotype:shZeb1 | Treatment:RSL3 (10 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n1_2h_sh-ZEB1_RSL3_1_uM_8 | Sample source:Breast cancer cells | Genotype:shZeb1 | Treatment:RSL3 (1 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n2_2h_sh-ZEB1_RSL3_1_uM_17 | Sample source:Breast cancer cells | Genotype:shZeb1 | Treatment:RSL3 (1 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n3_2h_sh-ZEB1_RSL3_1_uM_26 | Sample source:Breast cancer cells | Genotype:shZeb1 | Treatment:RSL3 (1 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n1_24h_DMSO_7 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:24 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n2_24h_DMSO_23 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:24 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n3_24h_DMSO_46 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:24 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n4_24h_DMSO_65 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:24 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n5_24h_DMSO_77 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:24 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n1_2h_DMSO_1 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n2_2h_RSL3_1uM_18 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n3_2h_DMSO_37 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n4_2h_DMSO_61 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n5_2h_DMSO_73 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n1_2h_WT_DMSO_1 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n2_2h_WT_DMSO_10 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n3_2h_WT_DMSO_19 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n1_4h_DMSO_3 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:4 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n2_4h_DMSO_19 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:4 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n3_4h_DMSO_40 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:4 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n1_6h_DMSO_5 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:6 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n2_6h_DMSO_21 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:6 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n3_6h_DMSO_43 | Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:6 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n3_24h_RSL3_10uM_48 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:24 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n4_24h_RSL3_10uM_66 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:24 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n5_24h_RSL3_10uM_78 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:24 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n3_2h_RSL3_10uM_39 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n4_2h_RSL3_10uM_62 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n5_2h_RSL3_10uM_74 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n1_2h_WT_RSL3_10_uM_3 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n2_2h_WT_RSL3_10_uM_12 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n3_2h_WT_RSL3_10_uM_21 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n3_4h_RSL3_10uM_42 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:4 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n4_4h_RSL3_10uM_63 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:4 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n5_4h_RSL3_10uM_75 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:4 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n3_6h_RSL3_10uM_45 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:6 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n4_6h_RSL3_10uM_64 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:6 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n5_6h_RSL3_10uM_76 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:6 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n1_24h_RSL3_1uM_8 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:24 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n2_24h_RSL3_1uM_24 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:24 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n3_24h_RSL3_1uM_47 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:24 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n1_2h_RSL3_1uM_2 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n2_2h_DMSO_17 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n3_2h_RSL3_1uM_38 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n1_2h_WT_RSL3_1_uM_2 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n2_2h_WT_RSL3_1_uM_11 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210514_MDA_ZEB1_n3_2h_WT_RSL3_1_uM_20 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:2 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n1_4h_RSL3_1uM_4 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:4 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n2_4h_RSL3_1uM_20 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:4 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n3_4h_RSL3_1uM_41 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:4 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n1_6h_RSL3_1uM_6 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:6 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n2_6h_RSL3_1uM_22 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:6 h | absolute intensities |
| Reversed phase NEGATIVE ION MODE | 210317_MDA_ZEB1_TC_pre_RSL3_WT_n3_6h_RSL3_1uM_44 | Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:6 h | absolute intensities |
Return to study ST003256 main page
Download data matrix(Exploration of Zeb1-dependent changes in the redox-lipidome of MDA-MB-231 cells Reversed phase NEGATIVE ION MODE)
- Metabolomics Workbench
|